Nasdaq btai.
The public float for BTAI is 20.22M, and currently, short sellers hold a 25.11% ratio of that floaft. The average trading volume of BTAI on November 30, 2023 was 3.17M shares. BTAI) stock’s latest price update. BioXcel Therapeutics Inc (NASDAQ: BTAI)’s stock price has dropped by -0.26 in relation to previous closing price of 3.91.
Shares of the commercial-stage biopharma BioXcel Therapeutics ( BTAI -2.02%) were up by 10.3% on heavy volume as of 3:29 p.m. ET Monday afternoon. The big gain came after the drugmaker reported ...If you’re familiar with investing, then you’ve probably heard of major stock exchanges like the New York Stock Exchange or the NASDAQ. Stock exchanges are sort of like a mixture between an auction house and a marketplace where investors can...View real-time BTAI stock price and news, along with industry-best analysis. ... Nasdaq, NYSE American and NYSE Arca listings. Sources: FactSet, Dow Jones. ETF Movers: Includes ETFs & ETNs with ...BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q3 2023 Earnings Call Transcript November 14, 2023 BioXcel Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-1.72 EPS, expectations ...BioXcel Therapeutics, Inc. (Nasdaq: BTAI) is a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience. The Company’s drug re-innovation ...
View real-time BTAI stock price and news, along with industry-best analysis. ... Nasdaq, NYSE American and NYSE Arca listings. Sources: FactSet, Dow Jones. ETF Movers: Includes ETFs & ETNs with ...
Nasdaq News: This is the News-site for the company Nasdaq on Markets Insider Indices Commodities Currencies Stocks
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BioXcel Therapeutics, Inc. - BTAI. NEW YORK , Aug. 28, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (NASDAQ: BTAI). Such investors are …NEW HAVEN, Conn., March 09, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop ...About Insider Activity. Nasdaq Insider Activity page provides trading information of corporate insiders (officers, directors and any beneficial owners of more than 10% of a class of the company ... See the latest BioXcel Therapeutics Inc stock price (BTAI:XNAS), related news, valuation, dividends and more to help you make your investing decisions.May 3, 2022 · NEW HAVEN, Conn., May 03, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop ...
The latest price target for . BioXcel Therapeutics (NASDAQ: BTAI) was reported by HC Wainwright & Co. on Wednesday, November 15, 2023.The analyst firm set a price target for 11.00 expecting BTAI ...
BioXcel Therapeutics, Inc. (Nasdaq: BTAI) is a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience. The Company’s drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning ...
NEW HAVEN, Conn., June 22, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence ...NEW YORK, Aug. 27, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that...21 Nov 2023 ... Find the latest dividend history for BioXcel Therapeutics, Inc. Common Stock (BTAI) at Nasdaq.com.BTAI stock is down 57.2% as of Thursday morning. That comes as some 3.2 million shares change hands, as compared to its daily average trading volume of about 549,000 shares. Investors seeking out ...NEW YORK, Aug. 27, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that...(NASDAQ: BTAI) Bioxcel Therapeutics currently has 29,272,671 outstanding shares. With Bioxcel Therapeutics stock trading at $3.80 per share, the total value of ...BioXcel Therapeutics, Inc. (Nasdaq: BTAI) is a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience. The Company’s drug re-innovation ...
BioXcel Therapeutics, Inc. Common Stock (BTAI) Nasdaq Listed. DATA AS OF Nov 12, 2021. 0. Add to Watchlist.BioXcel Therapeutics Inc Follow Share $3.93 After Hours: $3.90 (0.76%) -0.030 Closed: Nov 24, 4:39:38 PM GMT-5 · USD · NASDAQ · Disclaimer search Compare to Ardelyx Inc …BioXcel Therapeutics Inc. analyst ratings, historical stock prices, earnings estimates & actuals. BTAI updated stock price target summary.BioXcel Therapeutics (NASDAQ:BTAI) fell ~58% pre-market Thursday even after announcing that its Phase 3 trial for Alzheimer’s candidate BXCL501 reached its main goal as investors reacted to its ...BTAI technical analysis. This gauge displays a real-time technical analysis overview for your selected timeframe. The summary of BioXcel Therapeutics, Inc. is based on the most popular technical indicators, such as Moving Averages, Oscillators and Pivots. Learn more.BioXcel Therapeutics, Inc. (BTAI) NasdaqCM - NasdaqCM Real Time Price. Currency in USD Follow 2W 10W 9M 3.9000 +0.0700 (+1.83%) At close: 04:00PM EST 3.9999 +0.10 …Find the latest on short interest for BioXcel Therapeutics, Inc. Common Stock (BTAI) at Nasdaq.com.
Find the latest on option chains for BioXcel Therapeutics, Inc. Common Stock (BTAI) at Nasdaq.com.
BTAI's current price target is $23.88. Learn why top analysts are making this stock forecast for BioXcel Therapeutics at MarketBeat.Follow. NEW HAVEN, Conn., July 07, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial ...Nov 19, 2023 · BioXcel Therapeutics, Inc. (NASDAQ:BTAI – Free Report) – Equities research analysts at HC Wainwright reduced their FY2023 EPS estimates for BioXcel Therapeutics in a research note issued to investors on Wednesday, November 15th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings of ($6.63) per share for the year, down from […] BioXcel Therapeutics, Inc. (NASDAQ:BTAI) said the FDA has accepted for filing the new drug application for BXCL501, its investigational, orally dissolving thin film formulation of dexmedetomidine ...Over the past 3 months, 10 analysts have published their opinion on BioXcel Therapeutics (NASDAQ:BTAI) stock. These analysts are typically employed by large Wall Street banks and tasked with ...21 Feb 2023 ... BioXcel Therapeutics, Inc. [BTAI] Rings the Nasdaq Closing Bell.Aug 14, 2023 · BioXcel Therapeutics (NASDAQ: BTAI) stock is plummeting Monday. The clinical-stage biotech specialist's share price is down 44.6% as of 11:15 a.m. ET, according to data from S&P Global Market ... BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q3 2023 Earnings Call Transcript November 14, 2023 BioXcel Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-1.72 EPS, expectations were $-1.29. Operator: Good morning, and welcome to the BioXcel Therapeutics Conference Call, which will cover its alignment with the FDA on its ...Find the latest on short interest for BioXcel Therapeutics, Inc. Common Stock (BTAI) at Nasdaq.com.
BTAI U.S.: Nasdaq BioXcel Therapeutics Inc. Watch list NEW Set a price target alert Open Last Updated: Nov 30, 2023 11:20 a.m. EST Real time quote $ 3.8800 -0.0200 -0.51% Previous Close...
14 Aug 2023 ... BioXcel Therapeutics (BTAI 2.37%) stock is plummeting Monday. The clinical ... NASDAQ: BTAI. BioXcel Therapeutics. Today's Change. (2.37%) $0.09.
Find the latest on option chains for BioXcel Therapeutics, Inc. Common Stock (BTAI) at Nasdaq.com.BioXcel Therapeutics, Inc. (Nasdaq: BTAI) is a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience. The Company’s drug re-innovation ...NEW HAVEN, Conn., Aug. 10, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial ...BTAI U.S.: Nasdaq BioXcel Therapeutics Inc. Watch list NEW Set a price target alert Open Last Updated: Nov 30, 2023 11:20 a.m. EST Real time quote $ 3.8800 -0.0200 -0.51% Previous Close... BTAI: Get the latest BioXcel Therapeutics stock price and detailed information including BTAI news, historical charts and realtime prices. Indices Commodities Currencies Stocksanalyst Raghuram Selvaraju reiterates BioXcel Therapeutics (NASDAQ:BTAI) with a Buy and maintains $11 price target. Why Beyond Air Shares Are Trading Lower ...(Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today ...Nasdaq News: This is the News-site for the company Nasdaq on Markets Insider Indices Commodities Currencies StocksNEW HAVEN, Conn., Feb. 13, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative ...
NEW HAVEN, Conn., Dec. 22, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative ...NEW HAVEN, Conn., Feb. 13, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative ...BioXcel Therapeutics, Inc. (Nasdaq: BTAI) is a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology. The Company’s ...BioXcel Therapeutics (NASDAQ: BTAI) is another of the low-float, heavily-shorted penny stocks in the biotech space. Based on its “about us” page, BioXcel is riding the coattails of “AI Mania ...Instagram:https://instagram. how much is orthodontic insurancemtmvorbit bidbest workers comp insurance for small business in california BioXcel Therapeutics, Inc. (Nasdaq: BTAI) is a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience. The Company’s drug re-innovation ...More specifically, Citadel Investment Group was the largest shareholder of BioXcel Therapeutics, Inc. (NASDAQ:BTAI), with a stake worth $32.5 million reported as of the end of September. stock toolsadvance auto stocks Aug 14, 2023 · BioXcel Therapeutics (NASDAQ: BTAI) stock is plummeting Monday. The clinical-stage biotech specialist's share price is down 44.6% as of 11:15 a.m. ET, according to data from S&P Global Market ... Find the latest BioXcel Therapeutics, Inc. (BTAI) stock quote, history, news and other vital information to help you with your stock trading and investing. stocksofi Headquartered in New Haven, Connecticut, Bioxcel Therapeutics (NASDAQ:BTAI) might not seem that impressive of an enterprise at first glance.Since the beginning of this year, BTAI slipped almost 1% ...Nov 14, 2023 · BioXcel Therapeutics (NASDAQ:BTAI) reported its Q3 earnings results on Tuesday, November 14, 2023 at 07:00 AM.. Here's what investors need to know about the announcement. Earnings. BioXcel ... BioXcel Therapeutics, Inc. BTAI is a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience.